Our Smart Table automates the inventory process before, during, and after each procedure, saving time and resources while enhancing patient safety. Additionally, the system collects data points regarding instrument utilization for our downstream analytics platform in order to optimize surgical sets by surgeons and the procedures they perform.
14% of the operative time is spent counting surgical sponges alone (no metal instruments) because this is manually done it leads to 1 in 8 surgeries having a counting discrepancy. This leads to more time and risk for the patient. Worse yet, less than 20% of the instruments brought into the operating room are even utilized through the course of the procedure.
M&S Biotics is a 510k Class 1 (exempt) medical device and is currently in our soft launch phase, with our first pilot kicking off in 2023.
• M&S Biotics secured a partnership with AT&T and will deploy our product to their healthcare accounts.
o The first account is through the Veterans Healthcare Administration (VHA), starting with a fully paid pilot ($120,000) at Puget Sound, Washington.
• We are registered as a 510k Class 1 (exempt) device.
o Direct Sales and Co-Sale via AT&T
• M&S Biotics secured a partnership with AT&T and will deploy our product (co-sale) to their healthcare accounts.
o The first account is through the Veterans Healthcare Administration (VHA), starting with a fully paid pilot ($120,000) at Puget Sound, Washington.
o Three additional sites are in the process.
• IP- One PCT patent pending with a plan to file three more in 2023.
• Our Phase 1 NIH (NCATS) grant for $255,719 led to a publication in the IEEE journal: https://ieeexplore.ieee.org/document/9851422
• M&S Biotics is the first U.S Based Medical Device Company to partner with Johnson and Johnson’s Center for Device Innovation.
• M&S Biotics is a vendor through Health Trust Purchasing Group (HPG). A Group Purchasing Organization that sells to 1,400 hospitals.
• M&S Biotics has raised $2.6M in grants, capital, and competition prizes to get us to this stage, and we are currently targeting a Series A raise in 2023.
